Anika Therapeutics amended its credit line with Bank of America on July 10, 2026, increasing the total available to as much as $100 million. The revolving facility starts at $50 million with an option to borrow an additional $50 million. The loan matures in 2031, and interest is SOFR plus a margin based on the company's leverage. Anika pledged substantially all of its assets as collateral.
Who are the top institutional investors holding ANIKA THERAPEUTICS INC (ANIK)?
Major stakeholders currently include BlackRock, Inc. ($23.1M), Caligan Partners LP ($20.8M), Morgan Stanley ($12.6M). Based on the latest 13F filings, there are a total of 130 tracked investment funds and institutions maintaining positions in ANIK.
What is the overall institutional sentiment toward ANIK recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $61.8M, driven by 70 managers accumulating shares while 57 reduced their exposure.
Which institutions have been selling or reducing their ANIK positions?
In the latest period, 41 funds trimmed their holdings, and 16 managers completely exited their positions. The aggregate reported sell value was $57.1M.
Are there any notable investors adding ANIK to their portfolios?
Yes, buying activity remains notable. 20 institutions opened new positions in {ticker}, and 50 existing holders added to their shares. The total reported buy value for the quarter amounted to $67.9M.
Related Stocks
Trending Institutional Adds
The most-added stocks by 13F institutions this quarter